Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : DYAX: Dyax Corp. -- Ignore unavailable to you. Want to Upgrade?

To: nigel bates who wrote (12)	6/6/2001 11:15:58 AM
From: keokalani'nui	Read Replies (1) \| Respond to of 197

Borrowing from Nigel's post at CAT thread: >>CAT's patent portfolio includes about 30 families of patents, covering both technologies and products. CAT's core phage display technology is covered by three main families of patents:<< Message 15898981

To: nigel bates who wrote (12)	2/4/2002 1:41:31 PM
From: nigel bates	Read Replies (1) \| Respond to of 197

Just parking from the last 10K ...Our proprietary position in the field of phage display is based upon patent rights, technology, proprietary information, trade secrets and know-how. Our patents and patent applications for phage display include U.S. Patent Nos. 5,837,500, which expires June 29, 2010, 5,571,698, which expires June 29, 2010, 5,403,484, which expires April 4, 2012 and 5,223,409, which expires June 29, 2010, European Patent No. 436,597, which expires September 1, 2009, issued patents in Canada and Israel, and pending patent applications in the United States and other countries. These phage display patent rights contain claims covering inventions in the field of the surface display of proteins and certain other peptides, including surface display on bacteriophage...